|
1
|
Britt KL, Cuzick J and Phillips KA: Key
steps for effective breast cancer prevention. Nat Rev Cancer.
20:417–436. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Admoun C and Mayrovitz HN: The etiology of
breast cancer. Mayrovitz HN: Breast Cancer [Internet] Brisbane
(AU): Exon Publications; 2022, View Article : Google Scholar
|
|
3
|
Youn HJ and Han W: A review of the
epidemiology of breast cancer in Asia: Focus on risk factors. Asian
Pac J Cancer Prev. 21:867–880. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ligibel JA, Ballman KV, McCall L, Goodwin
PJ, Alfano CM, Bernstein V, Crane TE, Delahanty LM, Frank E, Hahn
O, et al: Impact of a weight loss intervention on 1-year weight
change in women with stage II/III breast cancer: Secondary analysis
of the breast cancer weight loss (BWEL) trial. JAMA Oncol.
11:1194–1203. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bellanger M, Lima SM, Cowppli-Bony A,
Molinié F and Terry MB: Effects of fertility on breast cancer
incidence trends: Comparing France and US. Cancer Causes Control.
32:903–910. 2021.PubMed/NCBI
|
|
6
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
7
|
Herdiana Y, Sriwidodo S, Sofian FF, Wilar
G and Diantini A: Nanoparticle-based antioxidants in stress
signaling and programmed cell death in breast cancer treatment.
Molecules. 28:53052023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Propper DJ and Balkwill FR: Harnessing
cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol.
19:237–253. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruggieri L, Moretti A, Berardi R, Cona MS,
Dalu D, Villa C, Chizzoniti D, Piva S, Gambaro A and La Verde N:
Host-related factors in the interplay among inflammation, immunity
and dormancy in breast cancer recurrence and prognosis: An overview
for clinicians. Int J Mol Sci. 24:49742023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li L, Yu R, Cai T, Chen Z, Lan M, Zou T,
Wang B, Wang Q, Zhao Y and Cai Y: Effects of immune cells and
cytokines on inflammation and immunosuppression in the tumor
microenvironment. Int Immunopharmacol. 88:1069392020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Habanjar O, Bingula R, Decombat C,
Diab-Assaf M, Caldefie-Chezet F and Delort L: Crosstalk of
inflammatory cytokines within the breast tumor microenvironment.
Int J Mol Sci. 24:40022023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng
J, Li Y, Wang X and Zhao L: Inflammatory responses and
inflammation-associated diseases in organs. Oncotarget.
9:7204–7218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu L, Abd Ghani MK, Aghemo A, Barh D,
Bassetti M, Catena F, Gallo G, Gholamrezanezhad A, Kamal MA, Lal A,
et al: SARS-CoV-2 infection, inflammation, immunonutrition, and
pathogenesis of COVID-19. Curr Med Chem. 30:4390–4408. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Li X, Yang M and Liu SB: Research
progress on morphology and mechanism of programmed cell death. Cell
Death Dis. 15:3272024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Della Torre L, Beato A, Capone V,
Carannante D, Verrilli G, Favale G, Del Gaudio N, Megchelenbrink
WL, Benedetti R, Altucci L and Carafa V: Involvement of regulated
cell deaths in aging and age-related pathologies. Ageing Res Rev.
95:1022512024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fernández-Lázaro D, Sanz B and Seco-Calvo
J: The mechanisms of regulated cell death: Structural and
functional proteomic pathways induced or inhibited by a specific
protein-A narrative review. Proteomes. 12:32024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qian S, Long Y, Tan G, Li X, Xiang B, Tao
Y, Xie Z and Zhang X: Programmed cell death: Molecular mechanisms,
biological functions, diseases, and therapeutic targets. MedComm
(2020). 5:e700242024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tong X, Tang R, Xiao M, Xu J, Wang W,
Zhang B, Liu J, Yu X and Shi S: Targeting cell death pathways for
cancer therapy: Recent developments in necroptosis, pyroptosis,
ferroptosis, and cuproptosis research. J Hematol Oncol. 15:1742022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He R, Liu Y, Fu W, He X, Liu S, Xiao D and
Tao Y: Mechanisms and cross-talk of regulated cell death and their
epigenetic modifications in tumor progression. Mol Cancer.
23:2672024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagata S: Apoptosis and clearance of
apoptotic cells. Annu Rev Immunol. 36:489–517. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patel AA, Ginhoux F and Yona S: Monocytes,
macrophages, dendritic cells and neutrophils: An update on lifespan
kinetics in health and disease. Immunology. 163:250–261. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Upton JW, Shubina M and Balachandran S:
RIPK3-driven cell death during virus infections. Immunol Rev.
277:90–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu L: Cell self-destruction (programmed
cell death), immunonutrition and metabolism. Biology (Basel).
12:9492023.PubMed/NCBI
|
|
24
|
Santagostino SF, Assenmacher CA, Tarrant
JC, Adedeji AO and Radaelli E: Mechanisms of regulated cell death:
Current perspectives. Vet Pathol. 58:596–623. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jorgensen I, Rayamajhi M and Miao EA:
Programmed cell death as a defence against infection. Nat Rev
Immunol. 17:151–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bekkering S, Domínguez-Andrés J, Joosten
LAB, Riksen NP and Netea MG: Trained immunity: Reprogramming innate
immunity in health and disease. Annu Rev Immunol. 39:667–693. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen X, Liu S, Goraya MU, Maarouf M, Huang
S and Chen JL: Host immune response to influenza A virus infection.
Front Immunol. 9:3202018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Purnamasari S and Hidayat R: The role of
natural physical, mechanical, and biochemical barriers as innate
immunity: A narrative literature review. Open Access Indones J Med
Rev. 3:361–364. 2023.
|
|
29
|
Place DE and Kanneganti TD: The innate
immune system and cell death in autoinflammatory and autoimmune
disease. Curr Opin Immunol. 67:95–105. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Molfetta R, Quatrini L, Santoni A and
Paolini R: Regulation of NKG2D-dependent NK cell functions: The Yin
and the Yang of receptor endocytosis. Int J Mol Sci. 18:16772017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ren X, Peng M, Xing P, Wei Y, Galbo PM Jr,
Corrigan D, Wang H, Su Y, Dong X, Sun Q, et al: Blockade of the
immunosuppressive KIR2DL5/PVR pathway elicits potent human NK
cell-mediated antitumor immunity. J Clin Invest. 132:e1636202022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Paolini R and Molfetta R: Dysregulation of
DNAM-1-mediated NK cell anti-cancer responses in the tumor
microenvironment. Cancers (Basel). 15:46162023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Voskoboinik I, Whisstock JC and Trapani
JA: Perforin and granzymes: Function, dysfunction and human
pathology. Nat Rev Immunol. 15:388–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin W, Luo Y, Wu J, Zhang H, Jin G, Guo C,
Zhou H, Liang H and Xu X: Loss of ADAR1 in macrophages in
combination with interferon gamma suppresses tumor growth by
remodeling the tumor microenvironment. J Immunother Cancer.
11:e0074022023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang S, Liu G, Li Y and Pan Y: Metabolic
reprogramming induces macrophage polarization in the tumor
microenvironment. Front Immunol. 13:8400292022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Boada-Romero E, Martinez J, Heckmann BL
and Green DR: The clearance of dead cells by efferocytosis. Nat Rev
Mol Cell Biol. 21:398–414. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Telser AG: Molecular biology of the cell,
4th edition. Shock. 18:2892002. View Article : Google Scholar
|
|
38
|
Li D and Wu M: Pattern recognition
receptors in health and diseases. Signal Transduct Target Ther.
6:2912021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Koike A, Tsujinaka K and Fujimori K:
Statins attenuate antiviral IFN-β and ISG expression via inhibition
of IRF3 and JAK/STAT signaling in poly(I:C)-treated hyperlipidemic
mice and macrophages. FEBS J. 288:4249–4266. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Turner MD, Nedjai B, Hurst T and
Pennington DJ: Cytokines and chemokines: At the crossroads of cell
signalling and inflammatory disease. Biochim Biophys Acta.
1843:2563–2582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ivashkiv LB and Donlin LT: Regulation of
type I interferon responses. Nat Rev Immunol. 14:36–49. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li G, Zhao X, Zheng Z, Zhang H, Wu Y, Shen
Y and Chen Q: cGAS-STING pathway mediates activation of dendritic
cell sensing of immunogenic tumors. Cell Mol Life Sci. 81:1492024.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dong H, Franklin NA, Ritchea SB, Yagita H,
Glennie MJ and Bullock TN: CD70 and IFN-1 selectively induce
eomesodermin or T-bet and synergize to promote CD8+ T-cell
responses. Eur J Immunol. 45:3289–3301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jo EK, Kim JK, Shin DM and Sasakawa C:
Molecular mechanisms regulating NLRP3 inflammasome activation. Cell
Mol Immunol. 13:148–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng M and Kanneganti TD: The regulation
of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis,
apoptosis, and necroptosis (PANoptosis). Immunol Rev. 297:26–38.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi J, Zhao Y, Wang K, Shi X, Wang Y,
Huang H, Zhuang Y, Cai T, Wang F and Shao F: Cleavage of GSDMD by
inflammatory caspases determines pyroptotic cell death. Nature.
526:660–665. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tengesdal IW, Li S, Powers NE, May M, Neff
CP, Joosten LAB, Marchetti C and Dinarello CA: Activation of
host-NLRP3 inflammasome in myeloid cells dictates response to
anti-PD-1 therapy in metastatic breast cancers. Pharmaceuticals
(Basel). 15:5742022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jing L, An Y, Cai T, Xiang J, Li B, Guo J,
Ma X, Wei L, Tian Y, Cheng X, et al: A subpopulation of
CD146+ macrophages enhances antitumor immunity by
activating the NLRP3 inflammasome. Cell Mol Immunol. 20:908–923.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yan L, Liu Y, Ma XF, Hou D, Zhang YH, Sun
Y, Shi SS, Forouzanfar T, Lin HY, Fan J and Wu G: Triclabendazole
induces pyroptosis by activating caspase-3 to cleave GSDME in
breast cancer cells. Front Pharmacol. 12:6700812021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Z, Zhang H, Li D, Zhou X, Qin Q and
Zhang Q: Caspase-3-mediated GSDME induced Pyroptosis in breast
cancer cells through the ROS/JNK signalling pathway. J Cell Mol
Med. 25:8159–8168. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang X, Cui X, Wang G, Zhou M, Wu Y, Du Y,
Li X and Xu T: HDAC inhibitor regulates the tumor immune
microenvironment via pyroptosis in triple negative breast cancer.
Mol Carcinog. 63:1800–1813. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Adams NM, Grassmann S and Sun JC: Clonal
expansion of innate and adaptive lymphocytes. Nat Rev Immunol.
20:694–707. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Boraschi D, Toepfer E and Italiani P:
Innate and germline immune memory: Specificity and heritability of
the ancient immune mechanisms for adaptation and survival. Front
Immunol. 15:13865782024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sette A and Crotty S: Adaptive immunity to
SARS-CoV-2 and COVID-19. Cell. 184:861–880. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fridman WH, Pagès F, Sautès-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Loi S, Drubay D, Adams S, Pruneri G,
Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria
S, et al: Tumor-infiltrating lymphocytes and prognosis: A pooled
individual patient analysis of early-stage triple-negative breast
cancers. J Clin Oncol. 37:559–569. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Herbert JA and Panagiotou S: Immune
response to viruses. Encycl Infect Immun. 1:429–444. 2022.
|
|
58
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Borst J, Ahrends T, Bąbała N, Melief CJM
and Kastenmüller W: CD4+ T cell help in cancer
immunology and immunotherapy. Nat Rev Immunol. 18:635–647. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Qian D, Li J, Huang M, Cui Q, Liu X and
Sun K: Dendritic cell vaccines in breast cancer: Immune modulation
and immunotherapy. Biomed Pharmacother. 162:1146852023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cai L and Li Y, Tan J, Xu L and Li Y:
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J
Hematol Oncol. 16:1012023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jin M, Fang J, Peng J, Wang X, Xing P, Jia
K, Hu J, Wang D, Ding Y, Wang X, et al: PD-1/PD-L1 immune
checkpoint blockade in breast cancer: Research insights and
sensitization strategies. Mol Cancer. 23:2662024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Schumacher TN and Thommen DS: Tertiary
lymphoid structures in cancer. Science. 375:eabf94192022.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Saxena M, van der Burg SH, Melief CJM and
Bhardwaj N: Therapeutic cancer vaccines. Nat Rev Cancer.
21:360–378. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chamorro DF, Somes LK and Hoyos V:
Engineered adoptive T-cell therapies for breast cancer: Current
progress, challenges, and potential. Cancers (Basel). 16:1242023.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cejuela M, Vethencourt A and Pernas S:
Immune checkpoint inhibitors and novel immunotherapy approaches for
breast cancer. Curr Oncol Rep. 24:1801–1819. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Duong E, Fessenden TB, Lutz E, Dinter T,
Yim L, Blatt S, Bhutkar A, Wittrup KD and Spranger S: Type I
interferon activates MHC class I-dressed CD11b+
conventional dendritic cells to promote protective anti-tumor
CD8+ T cell immunity. Immunity. 55:308–323.e9. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wu X, Huang Q, Chen X and Zhang B, Liang J
and Zhang B: B cells and tertiary lymphoid structures in tumors:
immunity cycle, clinical impact, and therapeutic applications.
Theranostics. 15:605–631. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Thol K, Pawlik P and McGranahan N: Therapy
sculpts the complex interplay between cancer and the immune system
during tumour evolution. Genome Med. 14:1372022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mirlekar B: Tumor promoting roles of
IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer
immunotherapy. SAGE Open Med. 10:205031212110690122022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li C, Jiang P, Wei S, Xu X and Wang J:
Regulatory T cells in tumor microenvironment: New mechanisms,
potential therapeutic strategies and future prospects. Mol Cancer.
19:1162020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ravichandran KS: Find-me and eat-me
signals in apoptotic cell clearance: Progress and conundrums. J Exp
Med. 207:1807–1817. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bertheloot D, Latz E and Franklin BS:
Necroptosis, pyroptosis and apoptosis: An intricate game of cell
death. Cell Mol Immunol. 18:1106–1121. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tanzer MC, Frauenstein A, Stafford CA,
Phulphagar K, Mann M and Meissner F: Quantitative and dynamic
catalogs of proteins released during apoptotic and necroptotic cell
death. Cell Rep. 30:1260–1270.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Nössing C and Ryan KM: 50 Years on and
still very much alive: ‘Apoptosis: A basic biological phenomenon
with wide-ranging implications in tissue kinetics’. Br J Cancer.
128:426–431. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wang R, Lan C, Benlagha K, Camara NOS,
Miller H, Kubo M, Heegaard S, Lee P, Yang L, Forsman H, et al: The
interaction of innate immune and adaptive immune system. MedComm
(2020). 5:e7142024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Moyer A, Tanaka K and Cheng EH: Apoptosis
in cancer biology and therapy. Annu Rev Pathol. 20:303–328. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Nagata S and Tanaka M: Programmed cell
death and the immune system. Nat Rev Immunol. 17:333–340. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Halkom A, Wu H and Lu Q: Contribution of
mouse models in our understanding of lupus. Int Rev Immunol.
39:174–187. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Rieux-Laucat F, Magérus-Chatinet A and
Neven B: The autoimmune lymphoproliferative syndrome with defective
FAS or FAS-ligand functions. J Clin Immunol. 38:558–568. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Leis K, Gałązka P, Kazik J, Jamrożek T,
Bereźnicka W and Czajkowski R: Resveratrol in the treatment of
asthma based on an animal model. Postepy Dermatol Alergol.
39:433–438. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Juric V, Hudson L, Fay J, Richards CE,
Jahns H, Verreault M, Bielle F, Idbaih A, Lamfers MLM, Hopkins AM,
et al: Transcriptional CDK inhibitors, CYC065 and THZ1 promote
Bim-dependent apoptosis in primary and recurrent GBM through cell
cycle arrest and Mcl-1 downregulation. Cell Death Dis. 12:7632021.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kotzin JJ, Spencer SP, McCright SJ, Kumar
DBU, Collet MA, Mowel WK, Elliott EN, Uyar A, Makiya MA, Dunagin
MC, et al: The long non-coding RNA Morrbid regulates Bim and
short-lived myeloid cell lifespan. Nature. 537:239–243. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Guo H, Yang Y, Lou Y, Zuo Z, Cui H, Deng
H, Zhu Y and Fang J: Apoptosis and DNA damage mediated by ROS
involved in male reproductive toxicity in mice induced by Nickel.
Ecotoxicol Environ Saf. 268:1156792023. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Green DR: The mitochondrial pathway of
apoptosis part II: The BCL-2 protein family. Cold Spring Harb
Perspect Biol. 14:a0410462022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Yadav N, Gogada R, O'Malley J, Gundampati
RK, Jayanthi S, Hashmi S, Lella R, Zhang D, Wang J, Kumar R, et al:
Molecular insights on cytochrome c and nucleotide regulation of
apoptosome function and its implication in cancer. Biochim Biophys
Acta Mol Cell Res. 1867:1185732020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Sahoo G, Samal D, Khandayataray P and
Murthy MK: A review on caspases: Key regulators of biological
activities and apoptosis. Mol Neurobiol. 60:5805–5837. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Shoshan-Barmatz V, Arif T and
Shteinfer-Kuzmine A: Apoptotic proteins with non-apoptotic
activity: Expression and function in cancer. Apoptosis. 28:730–753.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wang Y, Li Y, Wu Y, Wu A, Xiao B, Liu X,
Zhang Q, Feng Y, Yuan Z, Yi J, et al: Endoplasmic reticulum stress
promotes oxidative stress, inflammation, and apoptosis: A novel
mechanism of citrinin-induced renal injury and dysfunction.
Ecotoxicol Environ Saf. 284:1169462024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Fu X, Cui J, Meng X, Jiang P, Zheng Q,
Zhao W and Chen X: Endoplasmic reticulum stress, cell death and
tumor: Association between endoplasmic reticulum stress and the
apoptosis pathway in tumors (Review). Oncol Rep. 45:801–808. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Kara M and Oztas E: Endoplasmic reticulum
stress-mediated cell death. Program Cell Death. 1:1–14. 2020.
|
|
92
|
Wen N, Lv Q and Du ZG: MicroRNAs involved
in drug resistance of breast cancer by regulating autophagy. J
Zhejiang Univ Sci B. 21:690–702. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Liang DH, Choi DS, Ensor JE, Kaipparettu
BA, Bass BL and Chang JC: The autophagy inhibitor chloroquine
targets cancer stem cells in triple negative breast cancer by
inducing mitochondrial damage and impairing DNA break repair.
Cancer Lett. 376:249–258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Cook KL, Shajahan AN, Wärri A, Jin L,
Hilakivi-Clarke LA and Clarke R: Glucose-regulated protein 78
controls cross-talk between apoptosis and autophagy to determine
antiestrogen responsiveness. Cancer Res. 72:3337–3349. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Crawford AC, Riggins RB, Shajahan AN,
Zwart A and Clarke R: Co-inhibition of BCL-W and BCL2 restores
antiestrogen sensitivity through BECN1 and promotes an
autophagy-associated necrosis. PLoS One. 5:e86042010. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Thomas M, Davis T, Loos B, Sishi B,
Huisamen B, Strijdom H and Engelbrecht AM: Autophagy is essential
for the maintenance of amino acids and ATP levels during acute
amino acid starvation in MDAMB231 cells. Cell Biochem Funct.
36:65–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Martin S, Dudek-Peric AM, Garg AD, Roose
H, Demirsoy S, Van Eygen S, Mertens F, Vangheluwe P, Vankelecom H
and Agostinis P: An autophagy-driven pathway of ATP secretion
supports the aggressive phenotype of BRAFV600E
inhibitor-resistant metastatic melanoma cells. Autophagy.
13:1512–1527. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Bednarczyk M, Zmarzły N, Grabarek B,
Mazurek U and Muc-Wierzgoń M: Genes involved in the regulation of
different types of autophagy and their participation in cancer
pathogenesis. Oncotarget. 9:34413–34428. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Daskalaki I, Gkikas I and Tavernarakis N:
Hypoxia and selective autophagy in cancer development and therapy.
Front Cell Dev Biol. 6:1042018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Bousquet G, El Bouchtaoui M, Sophie T,
Leboeuf C, de Bazelaire C, Ratajczak P, Giacchetti S, de
Roquancourt A, Bertheau P, Verneuil L, et al: Targeting autophagic
cancer stem-cells to reverse chemoresistance in human triple
negative breast cancer. Oncotarget. 8:35205–35221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Yeo SK, Wen J, Chen S and Guan JL:
Autophagy differentially regulates distinct breast cancer stem-like
cells in murine models via EGFR/Stat3 and Tgfβ/Smad signaling.
Cancer Res. 76:3397–3410. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Vera-Ramirez L, Vodnala SK, Nini R, Hunter
KW and Green JE: Autophagy promotes the survival of dormant breast
cancer cells and metastatic tumour recurrence. Nat Commun.
9:19442018. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Gwinn DM, Shackelford DB, Egan DF,
Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK
phosphorylation of raptor mediates a metabolic checkpoint. Mol
Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Casimiro MC, Di Sante G, Di Rocco A, Loro
E, Pupo C, Pestell TG, Bisetto S, Velasco-Velázquez MA, Jiao X, Li
Z, et al: Cyclin D1 restrains oncogene-induced autophagy by
regulating the AMPK-LKB1 signaling axis. Cancer Res. 77:3391–3405.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Shi J, Gao W and Shao F: Pyroptosis:
Gasdermin-mediated programmed necrotic cell death. Trends Biochem
Sci. 42:245–254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Galluzzi L, Buqué A, Kepp O, Zitvogel L
and Kroemer G: Immunogenic cell death in cancer and infectious
disease. Nat Rev Immunol. 17:97–111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Kayagaki N, Stowe IB, Lee BL, O'Rourke K,
Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT,
et al: Caspase-11 cleaves gasdermin D for non-canonical
inflammasome signalling. Nature. 526:666–671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wang Y, Gao W, Shi X, Ding J, Liu W, He H,
Wang K and Shao F: Chemotherapy drugs induce pyroptosis through
caspase-3 cleavage of a gasdermin. Nature. 547:99–103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu
X, Junqueira C, Meza-Sosa KF, Mok TMY, Ansara J, et al: Gasdermin E
suppresses tumour growth by activating anti-tumour immunity.
Nature. 579:415–420. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang Q, Wang Y, Ding J, Wang C, Zhou X,
Gao W, Huang H, Shao F and Liu Z: A bioorthogonal system reveals
antitumour immune function of pyroptosis. Nature. 579:421–426.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang Y, Peng J, Mi X and Yang M: p53-GSDME
elevation: A path for CDK7 inhibition to suppress breast cancer
cell survival. Front Mol Biosci. 8:6974572021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Broderick NA: A common origin for immunity
and digestion. Front Immunol. 6:722015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Uribe-Querol E and Rosales C:
Phagocytosis: Our current understanding of a universal biological
process. Front Immunol. 11:10662020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kourtzelis I, Hajishengallis G and
Chavakis T: Phagocytosis of apoptotic cells in resolution of
inflammation. Front Immunol. 11:5532020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Sprooten J, Vanmeerbeek I, Datsi A,
Govaerts J, Naulaerts S, Laureano RS, Borràs DM, Calvet A, Malviya
V, Kuballa M, et al: Lymph node and tumor-associated
PD-L1+ macrophages antagonize dendritic cell vaccines by
suppressing CD8+ T cells. Cell Rep Med. 5:1013772024.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Kim HJ, Park JH, Kim HC, Kim CW, Kang I
and Lee HK: Blood monocyte-derived CD169+ macrophages
contribute to antitumor immunity against glioblastoma. Nat Commun.
13:62112022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Tang Z, Davidson D, Li R, Zhong MC, Qian
J, Chen J and Veillette A: Inflammatory macrophages exploit
unconventional pro-phagocytic integrins for phagocytosis and
anti-tumor immunity. Cell Rep. 37:1101112021. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Chen D, Varanasi SK, Hara T, Traina K, Sun
M, McDonald B, Farsakoglu Y, Clanton J, Xu S, Garcia-Rivera L, et
al: CTLA-4 blockade induces a microglia-Th1 cell partnership that
stimulates microglia phagocytosis and anti-tumor function in
glioblastoma. Immunity. 56:2086–2104.e8. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang
J, Zhao P, Fang L, Shi Y and Wang P: Emerging phagocytosis
checkpoints in cancer immunotherapy. Signal Transduct Target Ther.
8:1042023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Mantovani A, Allavena P, Marchesi F and
Garlanda C: Macrophages as tools and targets in cancer therapy. Nat
Rev Drug Discov. 21:799–820. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Gabriele M and Pucci L: Diet bioactive
compounds: implications for oxidative stress and inflammation in
the vascular system. Endocr Metab Immune Disord Drug Targets.
17:264–275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Stumpf F, Keller B, Gressies C and Schuetz
P: Inflammation and nutrition: Friend or foe? Nutrients.
15:11592023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ye J, Hu Y, Chen X, Chang C and Li K:
Comparative effects of different nutritional supplements on
inflammation, nutritional status, and clinical outcomes in
colorectal cancer patients: A systematic review and network
meta-analysis. Nutrients. 15:27722023. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Soeters PB, Wolfe RR and Shenkin A:
Hypoalbuminemia: Pathogenesis and clinical significance. JPEN J
Parenter Enteral Nutr. 43:181–193. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wiedermann CJ: Hypoalbuminemia as
surrogate and culprit of infections. Int J Mol Sci. 22:44962021.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Pan C, Gu Y and Ni Q: The prognostic value
of serum albumin to globulin ratio in patients with breast cancer:
A retrospective study. Breast Cancer (Dove Med Press). 16:403–411.
2024.PubMed/NCBI
|
|
127
|
Wei C, Ai H, Mo D, Wang P, Wei L, Liu Z,
Li P, Huang T and Liu M: A nomogram based on inflammation and
nutritional biomarkers for predicting the survival of breast cancer
patients. Front Endocrinol (Lausanne). 15:13888612024. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Xiang M, Zhang H, Tian J, Yuan Y, Xu Z and
Chen J: Low serum albumin levels and high neutrophil counts are
predictive of a poorer prognosis in patients with metastatic breast
cancer. Oncol Lett. 24:4322022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Al-Shaer AE, Buddenbaum N and Shaikh SR:
Polyunsaturated fatty acids, specialized pro-resolving mediators,
and targeting inflammation resolution in the age of precision
nutrition. Biochim Biophys Acta Mol Cell Biol Lipids.
1866:1589362021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Wautier JL and Wautier MP: Pro- and
anti-inflammatory prostaglandins and cytokines in humans: A mini
review. Int J Mol Sci. 24:96472023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Iddir M, Brito A, Dingeo G, Fernandez Del
Campo SS, Samouda H, La Frano MR and Bohn T: Strengthening the
immune system and reducing inflammation and oxidative stress
through diet and nutrition: Considerations during the COVID-19
crisis. Nutrients. 12:15622020. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Flores J, White BM, Brea RJ, Baskin JM and
Devaraj NK: Lipids: Chemical tools for their synthesis,
modification, and analysis. Chem Soc Rev. 49:4602–4614. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Choi RH, Tatum SM, Symons JD, Summers SA
and Holland WL: Ceramides and other sphingolipids as drivers of
cardiovascular disease. Nat Rev Cardiol. 18:701–711. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Yu B, Yu L and Klionsky DJ: Nutrition
acquisition by human immunity, transient overnutrition and the
cytokine storm in severe cases of COVID-19. Med Hypotheses.
155:1106682021. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Yoon H, Shaw JL, Haigis MC and Greka A:
Lipid metabolism in sickness and in health: Emerging regulators of
lipotoxicity. Mol Cell. 81:3708–3730. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ruan XZ, Varghese Z and Moorhead JF: An
update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol.
5:713–721. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Mitrofanova A, Merscher S and Fornoni A:
Kidney lipid dysmetabolism and lipid droplet accumulation in
chronic kidney disease. Nat Rev Nephrol. 19:629–645. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
D'Agati VD, Chagnac A, de Vries AP, Levi
M, Porrini E, Herman-Edelstein M and Praga M: Obesity-related
glomerulopathy: Clinical and pathologic characteristics and
pathogenesis. Nat Rev Nephrol. 12:453–471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Zhou P, Santoro A, Peroni OD, Nelson AT,
Saghatelian A, Siegel D and Kahn BB: PAHSAs enhance hepatic and
systemic insulin sensitivity through direct and indirect
mechanisms. J Clin Invest. 129:4138–4150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Bhat N and Mani A: Dysregulation of lipid
and glucose metabolism in nonalcoholic fatty liver disease.
Nutrients. 15:23232023. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Løvsletten NG, Bakke SS, Kase ET, Ouwens
DM, Thoresen GH and Rustan AC: Increased triacylglycerol-fatty acid
substrate cycling in human skeletal muscle cells exposed to
eicosapentaenoic acid. PLoS One. 13:e02080482018. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Jelenik T, Flögel U, Álvarez-Hernández E,
Scheiber D, Zweck E, Ding Z, Rothe M, Mastrototaro L, Kohlhaas V,
Kotzka J, et al: Insulin resistance and vulnerability to cardiac
ischemia. Diabetes. 67:2695–2702. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Ioannou MS, Jackson J, Sheu SH, Chang CL,
Weigel AV, Liu H, Pasolli HA, Xu CS, Pang S, Matthies D, et al:
Neuron-astrocyte metabolic coupling protects against
activity-induced fatty acid toxicity. Cell. 177:1522–1535.e14.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Wang Y, Qian Y, Fang Q, Zhong P, Li W,
Wang L, Fu W, Zhang Y, Xu Z, Li X and Liang G: Saturated palmitic
acid induces myocardial inflammatory injuries through direct
binding to TLR4 accessory protein MD2. Nat Commun. 8:139972017.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Nicholas DA, Zhang K, Hung C, Glasgow S,
Aruni AW, Unternaehrer J, Payne KJ, Langridge WHR and De Leon M:
Palmitic acid is a toll-like receptor 4 ligand that induces human
dendritic cell secretion of IL-1β. PLoS One. 12:e01767932017.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Tabas I: Consequences and therapeutic
implications of macrophage apoptosis in atherosclerosis: The
importance of lesion stage and phagocytic efficiency. Arterioscler
Thromb Vasc Biol. 25:2255–2264. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Neri CR, Scapaticci S, Chiarelli F and
Giannini C: Liver steatosis: A marker of metabolic risk in
children. Int J Mol Sci. 23:48222022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Jarczak D and Nierhaus A: Cytokine
storm-definition, causes, and implications. Int J Mol Sci.
23:117402022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Dinarello CA: Proinflammatory cytokines.
Chest. 118:503–508. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Nie J, Zhou L, Tian W, Liu X, Yang L, Yang
X, Zhang Y, Wei S, Wang DW and Wei J: Deep insight into cytokine
storm: From pathogenesis to treatment. Signal Transduct Target
Ther. 10:1122025. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Man SM, Karki R and Kanneganti TD:
Molecular mechanisms and functions of pyroptosis, inflammatory
caspases and inflammasomes in infectious diseases. Immunol Rev.
277:61–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Afzal S, Fiaz K, Noor A, Sindhu AS, Hanif
A, Bibi A, Asad M, Nawaz S, Zafar S, Ayub S, et al: Interrelated
oncogenic viruses and breast cancer. Front Mol Biosci.
9:7811112022. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Wu Q, Nie DY, Ba-Alawi W, Ji Y, Zhang Z,
Cruickshank J, Haight J, Ciamponi FE, Chen J, Duan S, et al: PRMT
inhibition induces a viral mimicry response in triple-negative
breast cancer. Nat Chem Biol. 18:821–830. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Zu Y, Ou Z, Wu D, Liu W, Liu L, Wu D, Zhao
Y, Ren P, Zhang Y, Li W, et al: Genetic characteristics of human
papillomavirus type 16, 18, 52 and 58 in southern China. Genomics.
113:3895–3906. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Khalil MI, Yang C, Vu L, Chadha S, Nabors
H, Welbon C, James CD, Morgan IM, Spanos WC and Pyeon D: HPV
upregulates MARCHF8 ubiquitin ligase and inhibits apoptosis by
degrading the death receptors in head and neck cancer. PLoS Pathog.
19:e10111712023. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Antonioli M, Pagni B, Vescovo T, Ellis R,
Cosway B, Rollo F, Bordoni V, Agrati C, Labus M, Covello R, et al:
HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by
inhibiting autophagy through E7-mediated degradation of AMBRA1.
Autophagy. 17:2842–2855. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Wyżewski Z, Mielcarska MB,
Gregorczyk-Zboroch KP and Myszka A: Virus-mediated inhibition of
apoptosis in the context of EBV-associated diseases: Molecular
mechanisms and therapeutic perspectives. Int J Mol Sci.
23:72652022. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Yu Z, Wang Y, Liu L, Zhang X, Jiang S and
Wang B: Apoptosis disorder, a key pathogenesis of HCMV-related
diseases. Int J Mol Sci. 22:41062021. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Gatti-Mays ME, Balko JM, Gameiro SR, Bear
HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky
K, et al: If we build it they will come: Targeting the immune
response to breast cancer. NPJ Breast Cancer. 5:372019. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Huang G, Zhou J, Chen J and Liu G:
Identification of pyroptosis related subtypes and tumor
microenvironment infiltration characteristics in breast cancer. Sci
Rep. 12:106402022. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Berkel C and Cacan E: Differential
expression and copy number variation of gasdermin (GSDM) family
members, pore-forming proteins in pyroptosis, in normal and
malignant serous ovarian tissue. Inflammation. 44:2203–2216. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Zhu C, Xu S, Jiang R, Yu Y, Bian J and Zou
Z: The gasdermin family: Emerging therapeutic targets in diseases.
Signal Transduct Target Ther. 9:872024. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Wu H, Qian D, Bai X and Sun S: Targeted
pyroptosis is a potential therapeutic strategy for cancer. J Oncol.
2022:25155252022. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Hu H, Yang H, Liu Y and Yan B:
Pathogenesis of anti-melanoma differentiation-associated gene 5
antibody-positive dermatomyositis: A concise review with an
emphasis on Type I interferon system. Front Med (Lausanne).
8:8331142022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Wu L, Lu H, Pan Y, Liu C, Wang J, Chen B
and Wang Y: The role of pyroptosis and its crosstalk with immune
therapy in breast cancer. Front Immunol. 13:9739352022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zhao Q, Huang L, Qin G, Qiao Y, Ren F,
Shen C, Wang S, Liu S, Lian J, Wang D, et al: Cancer-associated
fibroblasts induce monocytic myeloid-derived suppressor cell
generation via IL-6/exosomal miR-21-activated STAT3 signaling to
promote cisplatin resistance in esophageal squamous cell carcinoma.
Cancer Lett. 518:35–48. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Zaarour RF, Ribeiro M, Azzarone B, Kapoor
S and Chouaib S: Tumor microenvironment-induced tumor cell
plasticity: Relationship with hypoxic stress and impact on tumor
resistance. Front Oncol. 13:12225752023. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
169
|
Liao M, Qin R, Huang W, Zhu HP, Peng F,
Han B and Liu B: Targeting regulated cell death (RCD) with
small-molecule compounds in triple-negative breast cancer: A
revisited perspective from molecular mechanisms to targeted
therapies. J Hematol Oncol. 15:442022. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Attiq A and Afzal S: Trinity of
inflammation, innate immune cells and cross-talk of signalling
pathways in tumour microenvironment. Front Pharmacol.
14:12557272023. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Wang JL, Hua SN, Bao HJ, Yuan J, Zhao Y
and Chen S: Pyroptosis and inflammasomes in cancer and
inflammation. MedComm (2020). 4:e3742023. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Ji X, Huang X, Li C, Guan N, Pan T, Dong J
and Li L: Effect of tumor-associated macrophages on the pyroptosis
of breast cancer tumor cells. Cell Commun Signal. 21:1972023.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
van Beek JJP, Martens AWJ, Bakdash G and
de Vries IJM: Innate lymphoid cells in tumor immunity.
Biomedicines. 4:72016. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Spits H, Artis D, Colonna M, Diefenbach A,
Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius
RE, et al: Innate lymphoid cells-a proposal for uniform
nomenclature. Nat Rev Immunol. 13:145–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Verma D, Verma M and Mishra R: Stem cell
therapy and innate lymphoid cells. Stem Cells Int.
2022:35305202022. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Zhao M, Shao F, Yu D, Zhang J, Liu Z, Ma
J, Xia P and Wang S: Maturation and specialization of group 2
innate lymphoid cells through the lung-gut axis. Nat Commun.
13:76002022. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Srivastava RK, Sapra L, Bhardwaj A, Mishra
PK, Verma B and Baig Z: Unravelling the immunobiology of innate
lymphoid cells (ILCs): Implications in health and disease. Cytokine
Growth Factor Rev. 74:56–75. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Danziger N, Sokol ES, Graf RP, Hiemenz MC,
Maule J, Parimi V, Palmieri C, Pusztai L, Ross JS and Huang RSP:
Variable landscape of PD-L1 expression in breast carcinoma as
detected by the DAKO 22C3 immunohistochemistry assay. Oncologist.
28:319–326. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Levi I, Amsalem H, Nissan A, Darash-Yahana
M, Peretz T, Mandelboim O and Rachmilewitz J: Characterization of
tumor infiltrating natural killer cell subset. Oncotarget.
6:13835–13843. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Montaldo E, Vacca P, Chiossone L, Croxatto
D, Loiacono F, Martini S, Ferrero S, Walzer T, Moretta L and
Mingari MC: Unique eomes(+) NK cell subsets are present in uterus
and decidua during early pregnancy. Front Immunol. 6:6462016.
View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Salimi M, Wang R, Yao X, Li X, Wang X, Hu
Y, Chang X, Fan P, Dong T and Ogg G: Activated innate lymphoid cell
populations accumulate in human tumour tissues. BMC Cancer.
18:3412018. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Sivori S, Pende D, Quatrini L, Pietra G,
Della Chiesa M, Vacca P, Tumino N, Moretta F, Mingari MC, Locatelli
F and Moretta L: NK cells and ILCs in tumor immunotherapy. Mol
Aspects Med. 80:1008702021. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Fenis A, Demaria O, Gauthier L, Vivier E
and Narni-Mancinelli E: New immune cell engagers for cancer
immunotherapy. Nat Rev Immunol. 24:471–486. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Liu H, Wang Z, Zhou Y and Yang Y: MDSCs in
breast cancer: An important enabler of tumor progression and an
emerging therapeutic target. Front Immunol. 14:11992732023.
View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Nakasone ES, Hurvitz SA and McCann KE:
Harnessing the immune system in the battle against breast cancer.
Drugs Context. 7:2125202018. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Revel M, Daugan MV, Sautés-Fridman C,
Fridman WH and Roumenina LT: Complement system: Promoter or
suppressor of cancer progression? Antibodies (Basel). 9:572020.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Deslouches B and Di YP: Antimicrobial
peptides with selective antitumor mechanisms: Prospect for
anticancer applications. Oncotarget. 8:46635–46651. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Angelico G, Broggi G, Tinnirello G, Puzzo
L, Vecchio GM, Salvatorelli L, Memeo L, Santoro A, Farina J, Mulé
A, et al: Tumor infiltrating lymphocytes (TILS) and PD-L1
expression in breast cancer: A review of current evidence and
prognostic implications from Pathologist's perspective. Cancers
(Basel). 15:44792023. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Tang Y, Jiang Q, Ou Y, Zhang F, Qing K,
Sun Y, Lu W, Zhu H, Gong F, Lei P and Shen G: BIP induces mice
CD19(hi) regulatory B cells producing IL-10 and highly expressing
PD-L1, FasL. Mol Immunol. 69:44–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Burugu S, Asleh-Aburaya K and Nielsen TO:
Immune infiltrates in the breast cancer microenvironment:
Detection, characterization and clinical implication. Breast
Cancer. 24:3–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Shang Q, Yu X, Sun Q, Li H, Sun C and Liu
L: Polysaccharides regulate Th1/Th2 balance: A new strategy for
tumor immunotherapy. Biomed Pharmacother. 170:1159762024.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Togashi Y, Shitara K and Nishikawa H:
Regulatory T cells in cancer immunosuppression-implications for
anticancer therapy. Nat Rev Clin Oncol. 16:356–371. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Dolina JS, Van Braeckel-Budimir N, Thomas
GD and Salek-Ardakani S: CD8+ T cell exhaustion in
cancer. Front Immunol. 12:7152342021. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Sauer N, Matkowski I, Bodalska G, Murawski
M, Dzięgiel P and Calik J: Prognostic role of prolactin-induced
protein (PIP) in breast cancer. Cells. 12:22522023. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Lehmann BD, Colaprico A, Silva TC, Chen J,
An H, Ban Y, Huang H, Wang L, James JL, Balko JM, et al:
Multi-omics analysis identifies therapeutic vulnerabilities in
triple-negative breast cancer subtypes. Nat Commun. 12:62762021.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Truax AD, Thakkar M and Greer SF:
Dysregulated recruitment of the histone methyltransferase EZH2 to
the class II transactivator (CIITA) promoter IV in breast cancer
cells. PLoS One. 7:e360132012. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Kubaev A, Faez Sead F, Pirouzbakht M,
Nazari M, Riyahi H, Sargazi Aval O, Hasanvand A, Mousavi F and
Soleimani Samarkhazan H: Platelet-derived extracellular vesicles:
Emerging players in hemostasis and thrombosis. J Liposome Res.
35:334–344. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Han X, Song X, Xiao Z, Zhu G, Gao R, Ni B
and Li J: Study on the mechanism of MDSC-platelets and their role
in the breast cancer microenvironment. Front Cell Dev Biol.
12:13104422024. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Wang L, Zhang K, Feng J, Wang D and Liu J:
The progress of platelets in breast cancer. Cancer Manag Res.
15:811–821. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Mendoza-Almanza G, Burciaga-Hernández L,
Maldonado V, Melendez-Zajgla J and Olmos J: Role of platelets and
breast cancer stem cells in metastasis. World J Stem Cells.
12:1237–1254. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Catani MV, Savini I, Tullio V and Gasperi
V: The ‘Janus Face’ of platelets in cancer. Int J Mol Sci.
21:7882020. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Zielińska KA and Katanaev VL: The
signaling duo CXCL12 and CXCR4: Chemokine fuel for breast cancer
tumorigenesis. Cancers (Basel). 12:30712020. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Wang X, Zhao S, Wang Z and Gao T:
Platelets involved tumor cell EMT during circulation:
Communications and interventions. Cell Commun Signal. 20:822022.
View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Wang J, He Y, Hu F, Hu C, Sun Y, Yang K
and Yang S: Metabolic reprogramming of immune cells in the tumor
microenvironment. International Int J Mol Sci. 25:122232024.
View Article : Google Scholar
|
|
205
|
Singh L, Nair L, Kumar D, Arora MK, Bajaj
S, Gadewar M, Mishra SS, Rath SK, Dubey AK, Kaithwas G, et al:
Hypoxia induced lactate acidosis modulates tumor microenvironment
and lipid reprogramming to sustain the cancer cell survival. Front
Oncol. 13:10342052023. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Yan Y, Huang L, Liu Y, Yi M, Chu Q, Jiao D
and Wu K: Metabolic profiles of regulatory T cells and their
adaptations to the tumor microenvironment: Implications for
antitumor immunity. J Hematol Oncol. 15:1042022. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Guo R, Wang R, Zhang W, Li Y, Wang Y, Wang
H, Li X and Song J: Macrophage polarisation in the tumour
microenvironment: recent research advances and therapeutic
potential of different macrophage reprogramming. Cancer Control.
32:107327482513166042025. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Brand A, Singer K, Koehl GE, Kolitzus M,
Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, et
al: LDHA-associated lactic acid production blunts tumor
immunosurveillance by T and NK cells. Cell Metab. 24:657–671. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Chang CH, Qiu J, O'Sullivan D, Buck MD,
Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ,
et al: Metabolic competition in the tumor microenvironment is a
driver of cancer progression. Cell. 162:1229–1241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Xie J, Guo Z, Zhu Y, Ma M and Jia G:
Peripheral blood inflammatory indexes in breast cancer: A review.
Medicine (Baltimore). 102:e363152023. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Shibabaw T, Teferi B and Ayelign B: The
role of Th-17 cells and IL-17 in the metastatic spread of breast
cancer: As a means of prognosis and therapeutic target. Front
Immunol. 14:10948232023. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Danforth DN: The Role of chronic
inflammation in the development of breast cancer. (Basel).
13:39182021. View Article : Google Scholar
|
|
213
|
Ruan GT, Xie HL, Hu CL, Liu CA, Zhang HY,
Zhang Q, Wang ZW, Zhang X, Ge YZ, Lin SQ, et al: Comprehensive
prognostic effects of systemic inflammation and Insulin resistance
in women with breast cancer with different BMI: A prospective
multicenter cohort. Sci Rep. 13:43032023. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Egelston CA, Avalos C, Tu TY, Simons DL,
Jimenez G, Jung JY, Melstrom L, Margolin K, Yim JH, Kruper L, et
al: Human breast tumor-infiltrating CD8+ T cells retain
polyfunctionality despite PD-1 expression. Nat Commun. 9:42972018.
View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Hartman ZC, Poage GM, den Hollander P,
Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck
SG, Mills GB and Brown PH: Growth of triple-negative breast cancer
cells relies upon coordinate autocrine expression of the
proinflammatory cytokines IL-6 and IL-8. Cancer Res. 73:3470–3480.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Jin K, Pandey NB and Popel AS:
Simultaneous blockade of IL-6 and CCL5 signaling for synergistic
inhibition of triple-negative breast cancer growth and metastasis.
Breast Cancer Res. 20:542018. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Korkaya H, Kim GI, Davis A, Malik F, Henry
NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK,
et al: Activation of an IL6 inflammatory loop mediates trastuzumab
resistance in HER2+ breast cancer by expanding the cancer stem cell
population. Mol Cell. 47:570–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Yu H, Lin L, Zhang Z, Zhang H and Hu H:
Targeting NF-κB pathway for the therapy of diseases: Mechanism and
clinical study. Signal Transduct Target Ther. 5:2092020. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Li Z, Liu M, Li J, Yan G and Xu X:
Diosmetin alleviates AFB1-induced endoplasmic reticulum stress,
autophagy, and apoptosis via PI3K/AKT pathway in mice. Ecotoxicol
Environ Saf. 292:1179972025. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Diep S, Maddukuri M, Yamauchi S, Geshow G
and Delk NA: Interleukin-1 and nuclear factor kappa B signaling
promote breast cancer progression and treatment resistance. Cells.
11:16732022. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Xu J, Zhang J, Mao QF, Wu J and Wang Y:
The interaction between autophagy and JAK/STAT3 signaling pathway
in tumors. Front Genet. 13:8803592022. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Dai Z, Liu WC, Chen XY, Wang X, Li JL and
Zhang X: Gasdermin D-mediated pyroptosis: Mechanisms, diseases, and
inhibitors. Front Immunol. 14:11786622023. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Liu X, Xu X, Ye P, Jiang Z, Tian L, Yin Y
and Feng L: Genetic evidence for causal effects of inflammatory
protein factors on breast cancer. Discov Oncol. 16:14902025.
View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Liu F, Li L, Lan M, Zou T, Kong Z, Cai T,
Wu XY and Cai Y: Key factor regulating inflammatory
microenvironment, metastasis, and resistance in breast cancer:
Interleukin-1 signaling. Mediators Inflamm. 2021:77858902021.
View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Dong W, Gu X, Li J and Zhuang Z:
Characterization of immune landscape and prognostic value of
IL-17-related signature in invasive breast cancer. Transl Cancer
Res. 14:907–929. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Cui Y, Cui S, Lu W, Wang Y, Zhuo Z, Wang
R, Zhang D, Wu X, Chang L, Zuo X, et al: CRP, IL-1α, IL-1β, and
IL-6 levels and the risk of breast cancer: A two-sample Mendelian
randomization study. Sci Rep. 14:19822024. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Kehm RD, McDonald JA, Fenton SE,
Kavanaugh-Lynch M, Leung KA, McKenzie KE, Mandelblatt JS and Terry
MB: Inflammatory biomarkers and breast cancer risk: A systematic
review of the evidence and future potential for intervention
research. Int J Environ Res Public Health. 17:54452020. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Liang Y, He J, Chen X, Yin L, Yuan Q, Zeng
Q, Zu X and Shen Y: The emerging roles of metabolism in the
crosstalk between breast cancer cells and tumor-associated
macrophages. Int J Biol Sci. 19:4915–4930. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Liu J, Geng X, Hou J and Wu G: New
insights into M1/M2 macrophages: Key modulators in cancer
progression. Cancer Cell Int. 21:3892021. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Strizova Z, Benesova I, Bartolini R,
Novysedlak R, Cecrdlova E, Foley LK and Striz I: M1/M2 macrophages
and their overlaps-myth or reality? Clin Sci (Lond). 137:1067–1093.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Wang C, Lin Y, Zhu H, Zhou Y, Mao F, Huang
X, Sun Q and Li C: The prognostic and clinical value of
tumor-associated macrophages in patients with breast cancer: A
systematic review and meta-analysis. Front Oncol. 12:9058462022.
View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Wu C, Dong S, Huang R and Chen X:
Cancer-associated adipocytes and breast cancer: Intertwining in the
tumor microenvironment and challenges for cancer therapy. Cancers
(Basel). 15:7262023. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Maliniak ML, Miller-Kleinhenz J,
Cronin-Fenton DP, Lash TL, Gogineni K, Janssen EAM and McCullough
LE: Crown-like structures in breast adipose tissue: Early evidence
and current issues in breast cancer. Cancers (Basel). 13:22222021.
View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Zhang L: The role of mesenchymal stem
cells in modulating the breast cancer microenvironment. Cell
Transplant. 32:96368972312200732023. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Zheng J and Hao H: The importance of
cancer-associated fibroblasts in targeted therapies and drug
resistance in breast cancer. Front Oncol. 13:13338392023.
View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Rubinstein-Achiasaf L, Morein D,
Ben-Yaakov H, Liubomirski Y, Meshel T, Elbaz E, Dorot O, Pichinuk
E, Gershovits M, Weil M and Ben-Baruch A: Persistent inflammatory
stimulation drives the conversion of MSCs to inflammatory CAFs that
promote pro-metastatic characteristics in breast cancer cells.
Cancers (Basel). 13:14722021. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Chen Y, Yu D, Qian H, Shi Y and Tao Z:
CD8+ T cell-based cancer immunotherapy. J Transl Med.
22:3942024. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Bhandarkar V, Dinter T and Spranger S:
Architects of immunity: How dendritic cells shape CD8+ T
cell fate in cancer. Sci Immunol. 10:eadf47262025. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Giles JR, Globig AM, Kaech SM and Wherry
EJ: CD8+ T cells in the cancer-immunity cycle. Immunity.
56:2231–2253. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Tang D, Tang Q, Huang W, Zhang Y, Tian Y
and Fu X: Fasting: From physiology to pathology. Adv Sci (Weinh).
10:e22044872023. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Wilkinson MJ, Manoogian ENC, Zadourian A,
Lo H, Fakhouri S, Shoghi A, Wang X, Fleischer JG, Navlakha S, Panda
S and Taub PR: Ten-hour time-restricted eating reduces weight,
blood pressure, and atherogenic lipids in patients with metabolic
syndrome. Cell Metab. 31:92–104.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Yelek C, Mignion L, Paquot A, Bouzin C,
Corbet C, Muccioli GG, Cani PD and Jordan BF: Tumor metabolism is
affected by obesity in preclinical models of triple-negative breast
cancer. Cancers (Basel). 14:5622022. View Article : Google Scholar : PubMed/NCBI
|
|
244
|
James FR, Wootton S, Jackson A, Wiseman M,
Copson ER and Cutress RI: Obesity in breast cancer-what is the risk
factor? Eur J Cancer. 51:705–720. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Ng WH, Abu Zaid Z, Mohd Yusof BN, Amin
Nordin S and Lim PY: Association between dietary inflammatory index
and body fat percentage among newly diagnosed breast cancer
patients. Ann Med. 55:23033992023. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Savva C, Copson E, Johnson PWM, Cutress RI
and Beers SA: Obesity is associated with immunometabolic changes in
adipose tissue that may drive treatment resistance in breast
cancer: immune-metabolic reprogramming and novel therapeutic
strategies. Cancers (Basel). 15:24402023. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Calle EE and Kaaks R: Overweight, obesity
and cancer: Epidemiological evidence and proposed mechanisms. Nat
Rev Cancer. 4:579–591. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Gallagher EJ and LeRoith D: Obesity and
diabetes: The increased risk of cancer and cancer-related
mortality. Physiol Rev. 95:727–748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Ringel AE, Drijvers JM, Baker GJ, Catozzi
A, García-Cañaveras JC, Gassaway BM, Miller BC, Juneja VR, Nguyen
TH, Joshi S, et al: Obesity shapes metabolism in the tumor
microenvironment to suppress anti-tumor immunity. Cell.
183:1848–1866.e26. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Quail DF and Dannenberg AJ: The obese
adipose tissue microenvironment in cancer development and
progression. Nat Rev Endocrinol. 15:139–154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
251
|
Iyengar NM, Gucalp A, Dannenberg AJ and
Hudis CA: Obesity and cancer mechanisms: Tumor microenvironment and
inflammation. J Clin Oncol. 34:4270–4276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
252
|
Fortner RT, Katzke V, Kühn T and Kaaks R:
Obesity and breast cancer. Recent Results Cancer Res. 208:43–65.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Jiralerspong S and Goodwin PJ: Obesity and
breast cancer prognosis: Evidence, challenges, and opportunities. J
Clin Oncol. 34:4203–4216. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Suzuki R, Orsini N, Saji S, Key TJ and
Wolk A: Body weight and incidence of breast cancer defined by
estrogen and progesterone receptor status-a meta-analysis. Int J
Cancer. 124:698–712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Cecchini RS, Costantino JP, Cauley JA,
Cronin WM, Wickerham DL, Land SR, Weissfeld JL and Wolmark N: Body
mass index and the risk for developing invasive breast cancer among
high-risk women in NSABP P-1 and STAR breast cancer prevention
trials. Cancer Prev Res (Phila). 5:583–592. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
256
|
Chan DSM, Vieira AR, Aune D, Bandera EV,
Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R
and Norat T: Body mass index and survival in women with breast
cancer-systematic literature review and meta-analysis of 82
follow-up studies. Ann Oncol. 25:1901–1914. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Key TJ, Appleby PN, Reeves GK, Roddam A,
Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT,
Miller R, et al: Body mass index, serum sex hormones, and breast
cancer risk in postmenopausal women. J Natl Cancer Inst.
95:1218–1226. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
258
|
He M, Xu S, Yan F, Ruan J and Zhang X:
Fatty acid metabolism: A new perspective in breast cancer precision
therapy. Front Biosci (Landmark Ed). 28:3482023. View Article : Google Scholar : PubMed/NCBI
|
|
259
|
Guo R, Chen Y, Borgard H, Jijiwa M, Nasu
M, He M and Deng Y: The function and mechanism of lipid molecules
and their roles in the diagnosis and prognosis of breast cancer.
Molecules. 25:48682020. View Article : Google Scholar
|
|
260
|
Lu S and Archer MC: Sp1 coordinately
regulates de novo lipogenesis and proliferation in cancer cells.
Int J Cancer. 126:416–425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
261
|
Martin-Perez M, Urdiroz-Urricelqui U,
Bigas C and Benitah SA: The role of lipids in cancer progression
and metastasis. Cell Metab. 34:1675–1699. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
262
|
Solsona-Vilarrasa E and Vousden KH:
Obesity, white adipose tissue and cancer. FEBS J. 292:2189–2207.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
263
|
Kolb R, Kluz P, Tan ZW, Borcherding N,
Bormann N, Vishwakarma A, Balcziak L, Zhu P, Davies BS, Gourronc F,
et al: Obesity-associated inflammation promotes angiogenesis and
breast cancer via angiopoietin-like 4. Oncogene. 38:2351–2363.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
264
|
Magalhães A, Cesário V, Coutinho D, Matias
I, Domingues G, Pinheiro C, Serafim T and Dias S: A
high-cholesterol diet promotes the intravasation of breast tumor
cells through an LDL-LDLR axis. Sci Rep. 14:94712024. View Article : Google Scholar : PubMed/NCBI
|
|
265
|
Zipinotti Dos Santos D, de Souza JC,
Pimenta TM, da Silva Martins B, Junior RSR, Butzene SMS, Tessarolo
NG, Cilas PML Jr, Silva IV and Rangel LBA: The impact of lipid
metabolism on breast cancer: A review about its role in
tumorigenesis and immune escape. Cell Commun Signal. 21:1612023.
View Article : Google Scholar : PubMed/NCBI
|
|
266
|
Centonze G, Natalini D, Piccolantonio A,
Salemme V, Morellato A, Arina P, Riganti C and Defilippi P:
Cholesterol and its derivatives: Multifaceted players in breast
cancer progression. Front Oncol. 12:9066702022. View Article : Google Scholar : PubMed/NCBI
|
|
267
|
Li P, Zhang Z, Lv H and Sun P: Inhibiting
the expression of STARD3 induced apoptosis via the inactivation of
PI3K/AKT/mTOR pathway on ER+ breast cancer. Tissue Cell.
79:1019712022. View Article : Google Scholar : PubMed/NCBI
|
|
268
|
Bandyopadhayaya S, Akimov MG, Verma R,
Sharma A, Sharma D, Kundu GC, Gretskaya NM, Bezuglov VV and Mandal
CC: N-arachidonoyl dopamine inhibits epithelial-mesenchymal
transition of breast cancer cells through ERK signaling and
decreasing the cellular cholesterol. J Biochem Mol Toxicol.
35:e226932021. View Article : Google Scholar : PubMed/NCBI
|
|
269
|
Baek AE, Krawczynska N, Das Gupta A,
Dvoretskiy SV, You S, Park J, Deng YH, Sorrells JE, Smith BP, Ma L,
et al: The cholesterol metabolite 27HC increases secretion of
extracellular vesicles which promote breast cancer progression.
Endocrinology. 162:bqab0952021. View Article : Google Scholar : PubMed/NCBI
|
|
270
|
Godina C, Indira Chandran V, Barbachowska
M, Tryggvadottir H, Nodin B, Visse E, Borgquist S, Jirström K,
Isaksson K, Bosch A, et al: Interplay between caveolin-1 and body
and tumor size affects clinical outcomes in breast cancer. Transl
Oncol. 22:1014642022. View Article : Google Scholar : PubMed/NCBI
|
|
271
|
Trabert B, Bauer DC, Buist DSM, Cauley JA,
Falk RT, Geczik AM, Gierach GL, Hada M, Hue TF, Lacey JV Jr, et al:
Association of circulating progesterone with breast cancer risk
among postmenopausal women. JAMA Netw Open. 3:e2036452020.
View Article : Google Scholar : PubMed/NCBI
|
|
272
|
Mohanty SS and Mohanty PK: Obesity as
potential breast cancer risk factor for postmenopausal women. Genes
Dis. 8:117–123. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
273
|
Glassman I, Le N, Asif A, Goulding A,
Alcantara CA, Vu A, Chorbajian A, Mirhosseini M, Singh M and
Venketaraman V: The role of obesity in breast cancer pathogenesis.
Cells. 12:20612023. View Article : Google Scholar : PubMed/NCBI
|
|
274
|
Dong S, Wang Z, Shen K and Chen X:
Metabolic syndrome and breast cancer: Prevalence, treatment
response, and prognosis. Front Oncol. 11:6296662021. View Article : Google Scholar : PubMed/NCBI
|
|
275
|
Zhao X, An X, Yang C, Sun W, Ji H and Lian
F: The crucial role and mechanism of insulin resistance in
metabolic disease. Front Endocrinol (Lausanne). 14:11492392023.
View Article : Google Scholar : PubMed/NCBI
|
|
276
|
Dieli-Conwright CM, Wong L, Waliany S and
Mortimer JE: Metabolic syndrome and breast cancer survivors: A
follow-up analysis after completion of chemotherapy. Diabetol Metab
Syndr. 14:362022. View Article : Google Scholar : PubMed/NCBI
|
|
277
|
Viedma-Rodríguez R, Martínez-Hernández MG,
Martínez-Torres DI and Baiza-Gutman LA: Epithelial mesenchymal
transition and progression of breast cancer promoted by diabetes
mellitus in mice are associated with increased expression of
glycolytic and proteolytic enzymes. Horm Cancer. 11:170–181. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
278
|
Rahman MM, Behl T, Islam MR, Alam MN,
Islam MM, Albarrati A, Albratty M, Meraya AM and Bungau SG:
Emerging management approach for the adverse events of
immunotherapy of cancer. Molecules. 27:37982022. View Article : Google Scholar : PubMed/NCBI
|
|
279
|
Mehanna J, Haddad FG, Eid R, Lambertini M
and Kourie HR: Triple-negative breast cancer: Current perspective
on the evolving therapeutic landscape. Int J Womens Health.
11:431–437. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
280
|
Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS,
Kumar A, Vishakha Behl T, Jha SK and Tang H: Advancements in
clinical aspects of targeted therapy and immunotherapy in breast
cancer. Mol Cancer. 22:1052023. View Article : Google Scholar : PubMed/NCBI
|
|
281
|
Morrow RJ, Allam AH, Yeo B, Deb S, Murone
C, Lim E, Johnstone CN and Ernst M: Paracrine IL-6 signaling
confers proliferation between heterogeneous inflammatory breast
cancer sub-clones. Cancers (Basel). 14:22922022. View Article : Google Scholar : PubMed/NCBI
|
|
282
|
Manore SG, Doheny DL, Wong GL and Lo HW:
IL-6/JAK/STAT3 signaling in breast cancer metastasis: Biology and
treatment. Front Oncol. 12:8660142022. View Article : Google Scholar : PubMed/NCBI
|
|
283
|
Ding R, Kan Q, Wang T, Xiao R, Song Y and
Li D: Ginsenoside Rh2 regulates triple-negative breast cancer
proliferation and apoptosis via the IL-6/JAK2/STAT3 pathway. Front
Pharmacol. 15:14838962025. View Article : Google Scholar : PubMed/NCBI
|
|
284
|
Sun X, Liu K, Lu S, He W and Du Z:
Targeted therapy and immunotherapy for heterogeneous breast cancer.
Cancers (Basel). 14:54562022. View Article : Google Scholar : PubMed/NCBI
|
|
285
|
Swain SM, Shastry M and Hamilton E:
Targeting HER2-positive breast cancer: Advances and future
directions. Nat Rev Drug Discov. 22:101–126. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
286
|
Maadi H, Soheilifar MH, Choi WS,
Moshtaghian A and Wang Z: Trastuzumab mechanism of action; 20 years
of research to unravel a dilemma. Cancers (Basel). 13:35402021.
View Article : Google Scholar : PubMed/NCBI
|
|
287
|
Li F and Liu S: Focusing on NK cells and
ADCC: A promising immunotherapy approach in targeted therapy for
HER2-positive breast cancer. Front Immunol. 13:10834622022.
View Article : Google Scholar : PubMed/NCBI
|
|
288
|
Mandó P, Rivero SG, Rizzo MM, Pinkasz M
and Levy EM: Targeting ADCC: A different approach to HER2 breast
cancer in the immunotherapy era. Breast. 60:15–25. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
289
|
Waks AG, Martínez-Sáez O, Tarantino P,
Braso-Maristany F, Pascual T, Cortés J, Tolaney SM and Prat A: Dual
HER2 inhibition: Mechanisms of synergy, patient selection, and
resistance. Nat Rev Clin Oncol. 21:818–832. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
290
|
Yeh R, O'Donoghue JA, Jayaprakasam VS,
Mauguen A, Min R, Park S, Brockway JP, Bromberg JF, Zhi WI, Robson
ME, et al: First-in-human evaluation of site-specifically labeled
89Zr-pertuzumab in patients with HER2-positive breast
cancer. J Nucl Med. 65:386–393. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
291
|
García-Aranda M and Redondo M: Protein
kinase targets in breast cancer. Int J Mol Sci. 18:25432017.
View Article : Google Scholar : PubMed/NCBI
|
|
292
|
Zhang S, Chen W, Zhou J, Liang Q, Zhang Y,
Su M, Zhang Z and Qu J: The benefits and safety of monoclonal
antibodies: implications for cancer immunotherapy. J Inflamm Res.
18:4335–4357. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
293
|
Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G,
Hou P, Cui Q, Xu Z, Wang W, et al: Antibody-drug conjugates (ADCs):
Current and future biopharmaceuticals. J Hematol Oncol. 18:512025.
View Article : Google Scholar : PubMed/NCBI
|
|
294
|
Torres ETR and Emens LA: Emerging
combination immunotherapy strategies for breast cancer: Dual immune
checkpoint modulation, antibody-drug conjugates and bispecific
antibodies. Breast Cancer Res Treat. 191:291–302. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
295
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and nab-paclitaxel in advanced triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
296
|
Cortes J, Cescon DW, Rugo HS, Nowecki Z,
Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et
al: Pembrolizumab plus chemotherapy versus placebo plus
chemotherapy for previously untreated locally recurrent inoperable
or metastatic triple-negative breast cancer (KEYNOTE-355): A
randomised, placebo-controlled, double-blind, phase 3 clinical
trial. Lancet. 396:1817–1828. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
297
|
Ayoub NM, Al-Shami KM and Yaghan RJ:
Immunotherapy for HER2-positive breast cancer: Recent advances and
combination therapeutic approaches. Breast Cancer (Dove Med Press).
11:53–69. 2019.PubMed/NCBI
|
|
298
|
Mittendorf EA, Zhang H, Barrios CH, Saji
S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al:
Neoadjuvant atezolizumab in combination with sequential
nab-paclitaxel and anthracycline-based chemotherapy versus placebo
and chemotherapy in patients with early-stage triple-negative
breast cancer (IMpassion031): A randomised, double-blind, phase 3
trial. Lancet. 396:1090–1100. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
299
|
Pusztai L, Yau C, Wolf DM, Han HS, Du L,
Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, et al:
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative
stage II/III breast cancer: Results from the adaptively randomized
I-SPY2 trial. Cancer Cell. 39:989–998.e5. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
300
|
El Bairi K, Haynes HR, Blackley E,
Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC,
Gharib M, et al: The tale of TILs in breast cancer: A report from
the international immuno-oncology biomarker working group. NPJ
Breast Cancer. 7:1502021. View Article : Google Scholar : PubMed/NCBI
|
|
301
|
Loi S, Salgado R, Adams S, Pruneri G,
Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria
S, et al: Tumor infiltrating lymphocyte stratification of
prognostic staging of early-stage triple negative breast cancer.
NPJ Breast Cancer. 8:32022. View Article : Google Scholar : PubMed/NCBI
|
|
302
|
Moisand A, Madéry M, Boyer T, Domblides C,
Blaye C and Larmonier N: Hormone receptor signaling and breast
cancer resistance to anti-tumor immunity. Int J Mol Sci.
24:150482023. View Article : Google Scholar : PubMed/NCBI
|
|
303
|
Axelrod ML, Cook RS, Johnson DB and Balko
JM: Biological consequences of MHC-II expression by tumor cells in
cancer. Clin Cancer Res. 25:2392–2402. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
304
|
Smith PL, Piadel K and Dalgleish AG:
Directing T-cell immune responses for cancer vaccination and
immunotherapy. Vaccines (Basel). 9:13922021. View Article : Google Scholar : PubMed/NCBI
|
|
305
|
Mittendorf EA, Clifton GT, Holmes JP,
Schneble E, van Echo D, Ponniah S and Peoples GE: Final report of
the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine
with booster inoculations to prevent disease recurrence in
high-risk breast cancer patients. Ann Oncol. 25:1735–1742. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
306
|
Carmichael MG, Benavides LC, Holmes JP,
Gates JD, Mittendorf EA, Ponniah S and Peoples GE: Results of the
first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine
in disease-free breast cancer patients: United States military
cancer institute clinical trials group study I-04. Cancer.
116:292–301. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
307
|
McCarthy PM, Clifton GT, Vreeland TJ,
Adams AM, O'Shea AE and Peoples GE: AE37: A HER2-targeted vaccine
for the prevention of breast cancer recurrence. Expert Opin
Investig Drugs. 30:5–11. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
308
|
Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J,
Zhang Z, Qiu P and Gu X: Advances in immunotherapy for
triple-negative breast cancer. Mol Cancer. 22:1452023. View Article : Google Scholar : PubMed/NCBI
|
|
309
|
Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel
C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, et al: A
phase II clinical trial of pembrolizumab and enobosarm in patients
with androgen receptor-positive metastatic triple-negative breast
cancer. Oncologist. 26:99–e217. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
310
|
Wood SJ, Gao Y, Lee JH, Chen J, Wang Q,
Meisel JL and Li X: High tumor infiltrating lymphocytes are
significantly associated with pathological complete response in
triple negative breast cancer treated with neoadjuvant KEYNOTE-522
chemoimmunotherapy. Breast Cancer Res Treat. 205:193–199. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
311
|
Cardoso F, O'Shaughnessy J, Liu Z,
McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW,
Fasching PA, et al: Pembrolizumab and chemotherapy in high-risk,
early-stage, ER+/HER2− breast cancer: A
randomized phase 3 trial. Nat Med. 31:442–448. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
312
|
Thuya WL, Cao Y, Ho PC, Wong AL, Wang L,
Zhou J, Nicot C and Goh BC: Insights into IL-6/JAK/STAT3 signaling
in the tumor microenvironment: Implications for cancer therapy.
Cytokine Growth Factor Rev. 85:26–42. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
313
|
Kahaer G, Pan S, Yang C, Xie W and Lu Y:
Dual function of Gasdermin E: Pyroptosis-mediated pan-cancer
suppression versus HCC-specific oncogenic activity. Front Immunol.
16:16263112025. View Article : Google Scholar : PubMed/NCBI
|
|
314
|
Yang J, Xu J, Wang W, Zhang B, Yu X and
Shi S: Epigenetic regulation in the tumor microenvironment:
Molecular mechanisms and therapeutic targets. Signal Transduct
Target Ther. 8:2102023. View Article : Google Scholar : PubMed/NCBI
|
|
315
|
Kwon YY and Hui S: IL-6 promotes tumor
growth through immune evasion but is dispensable for cachexia. EMBO
Rep. 25:2592–2609. 2024. View Article : Google Scholar : PubMed/NCBI
|
